Mika Health Collaborates with AstraZeneca and Daiichi Sankyo to Deliver AI-Enabled Mobile Support to Women Undergoing Breast Cancer Treatment
June 18, 2024 13:36 ET
|
MIKA Health
Breast cancer patients access AI-enabled mobile digital therapeutic to supplement pharmaceutical therapy.
Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer
June 18, 2024 09:00 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., June 18, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
June 18, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
Oncocyte Appoints Andrea James as Chief Financial Officer
June 17, 2024 16:05 ET
|
OncoCyte Corporation
Oncocyte Appoints Seasoned Finance Executive Andrea James as Chief Financial Officer
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
June 17, 2024 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,...
Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating Hard-to-Treat T-ALL/LBL; Data Presented Today at European Hematology Association (EHA) 2024 Hybrid Congress
June 14, 2024 07:30 ET
|
Wugen
Wugen Presents Data at European Hematology Association (EHA) 2024 Hybrid Congress
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
June 14, 2024 07:00 ET
|
Kymera Therapeutics, Inc.
KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma Robust STAT3 knockdown and...
Findings from landmark RESONATE-2 study confirm sustained survival benefit of IMBRUVICA® (ibrutinib) for first-line chronic lymphocytic leukaemia treatment with up to 10 years follow-up
June 14, 2024 03:00 ET
|
Janssen Cilag International NV
RESONATE-2 data presented at the 2024 European Hematology Association (EHA) Congress provide longest-term outcomes and safety data ever reported for a monotherapy BTK inhibitor, with a median PFS of...
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
June 13, 2024 16:01 ET
|
IN8bio, Inc
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236
June 13, 2024 08:15 ET
|
CERo Therapeutics Holdings, Inc.
Company anticipates near term filing of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO)...